VOR · Vor Biopharma
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $25.10
Note written ·
Price against the kill line
22.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $25.10, on record since 11 November 2026. The shares are down 15.6% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $25.10, near the September high and 29.9% over the last close, which would show the shares leading the S&P 500 despite the dilution. A UPSTREAM MG topline that beats its efficacy endpoint ahead of the first-half 2027 guide would also show the shares leading.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 30 October 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −120
- Net cash, cash less debt ($M)
- 482
- Price to earnings (×)
- 0.9
- Free-cash-flow yield (%)
- −10.0
All filed numbers
What Vor Biopharma reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: 1,354 | −86.7 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +793.0 |
| Operating cash flow ($M) | −119 |
| Capital spending ($M) | 0.5 |
| Free cash flow ($M) | −120 |
| Cash and short-term investments ($M) | 482 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 482 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | −137 |
| Market value ($M) | 1,193 |
| Enterprise value, market value plus net debt ($M) no debt reported | 712 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | 0.9 |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −10.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 12.1% of shares outstanding sold short, 9.0 days of average trading to cover, −4.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $49.4M |
The thesis
Vor Biopharma is more likely to lag the S&P 500 over the next three months. Its value rests on the global UPSTREAM MG Phase 3 trial of telitacicept in generalized myasthenia gravis, whose 24-week topline the company guides to the first half of 2027, and that result is outside the three-month window. Inside it, share supply and a widening pipeline are the news: a $150 million common-share prospectus reported on 30 October 2026, and on 12 November 2026 an amended RemeGen license adding a second drug, RC298.
The shares closed at $19.32 on 12 November 2026, down from $20.09 on 11 November 2026. That is 25.7% below the 52-week intraday high of $26.00 on 8 September 2026. The 50-day average is $20.09 and the 200-day average is $17.50, both adjusted. The shares are down 16.1% over three months from the $23.03 close on 14 August 2026.
Vor's 12 November 2026 release says the amendment adds RC298, a long-acting dual BAFF/APRIL inhibitor (it blocks two proteins that drive B-cell activity in autoimmune disease), to its license outside Greater China. Upfront consideration is about $56 million: $10 million in cash plus pre-funded warrants for 2.3 million shares valued at about $46 million, with up to $300 million of development milestones. A China investigational new drug filing for RC298 is expected in the first half of 2027. Vor reaffirmed funding into early 2029.
Revenue is not part of the case. Vor has no approved product, and telitacicept is approved only in China, where RemeGen holds the rights.
Bullish and bearish views on Vor Biopharma Inc.
The bull case on Vor Biopharma Inc. (VOR), in brief: pivotal enrollment is finished. The bear case: Global efficacy is unproven.
Bull case
- Pivotal enrollment is finished. Vor's 30 October 2026 report says UPSTREAM MG is fully enrolled and the topline is still expected in the first half of 2027. UPSTREAM SjD, the Sjögren's disease trial, is still enrolling.
- Cash funds operations into early 2029. Vor reported $481.6 million of cash, equivalents and marketable securities at 30 September 2026 and reaffirmed funding into early 2029 on 12 November 2026. The RC298 cash payment is $10 million.
- Two-year kidney data are strong. In the China IgA nephropathy trial run by RemeGen, the annualized eGFR slope (a measure of kidney filtering rate) was −0.6 on telitacicept versus −5.7 on placebo, a 5.1 difference with p<0.001, per Vor's 22 October 2026 release. There were no kidney failure events on telitacicept versus five on placebo.
- RC298 extends the franchise. The 12 November 2026 amendment gives Vor rights outside Greater China to a second BAFF/APRIL drug, which RemeGen develops through Phase 1 before Vor takes over. The upfront cost is mostly warrants.
- Net loss narrowed on an accounting item. Vor reported a third-quarter 2026 net loss of $86.7 million versus $812.7 million a year earlier, mainly from the change in fair value of liability-classified warrants. It is not an operating gain.
Bear case
- Global efficacy is unproven. The UPSTREAM MG primary endpoint is the 24-week change in the MG-ADL score (Myasthenia Gravis Activities of Daily Living). A result that is not statistically significant would break the clinical case.
- Share supply keeps appearing. Vor raised $48.4 million of net proceeds through at-the-market share sales in July 2026 (Q2 results, 11 August 2026). A $150 million common-share prospectus was reported on 30 October 2026, and the 12 November 2026 8-K lists an unregistered sale of equity securities, which matches the RC298 pre-funded warrants.
- Operating spending is rising. Research and development expense was $34.5 million in the third quarter of 2026 versus $14.1 million a year earlier. General and administrative expense was $23.9 million versus $14.0 million (Q3 2026 results, 30 October 2026).
- The new drug is at the earliest stage. RC298 is in IND-enabling development, with a China IND submission expected in the first half of 2027 (Vor release, 12 November 2026). It adds up to $300 million of milestone obligations without clinical data.
- China data may not carry over. Vor's rights exclude Greater China. The 22 October 2026 release says Vor has not independently verified the RemeGen-reported TELIGAN data, and it lists the risk that regulators outside China may not accept data generated there.
- Safety signals are visible. The 22 October 2026 release reported injection-site reactions in 56.0% of telitacicept patients versus 18.9% on placebo.
Price setup
The shares closed at $19.32 on 12 November 2026, below the 50-day average of $20.09 and above the 200-day average of $17.50. The closes ran $18.66 on 5 November 2026, $19.88 on 6 November 2026, $19.98 on 9 November 2026, $19.56 on 10 November 2026 and $20.09 on 11 November 2026. The 52-week closing low was $6.86 on 20 November 2025.
The pre-funded warrants in the RC298 deal were valued by Vor at about $46 million using the 11 November 2026 close of $20.09. SEC filings show a Form 4 on 4 November 2026 for Chief Medical Officer Jeremy Sokolove, covering 1,917 shares withheld for tax at $19.25 on 2 November 2026. No open-market insider sales appear in the recent Form 4 filings.
Catalysts ahead
- 17 November 2026: Vor Bio presentation at the Jefferies Global Healthcare Conference in London. Management commentary on the RC298 deal, the share filing and the UPSTREAM MG timeline could confirm or change the first-half 2027 topline guide.
- 30 June 2027: End of Vor's guided first-half 2027 window for the UPSTREAM MG 24-week topline. Decides whether the efficacy signal seen in China reproduces in the global registrational trial.
What would change the view
A daily close above $25.10, near the September high and 29.9% over the last close, which would show the shares leading the S&P 500 despite the dilution. A UPSTREAM MG topline that beats its efficacy endpoint ahead of the first-half 2027 guide would also show the shares leading.
What it trades with
Vor trades on its own clinical timeline and on sentiment toward small and mid-sized biotech shares that depend on a single drug. Its drug and its new RC298 license both come from RemeGen, so RemeGen's China results and any safety news can move Vor's shares. The biotech index and the equity-financing market affect how easily Vor can sell the further shares it has used in 2025 and 2026.
The evidence, claim by claim (8)
- Cash, cash equivalents and marketable securities totaled $481.6 million at 30 September 2026; Vor guides funding into early 2029. Vor Bio third-quarter 2026 results, 30 October 2026 · as of
- Vor added RC298 to its RemeGen license outside Greater China for about $56 million upfront ($10 million cash plus pre-funded warrants for 2.3 million shares) and up to $300 million of development milestones. Vor Bio release, 12 November 2026 · as of
- Third-quarter 2026 net loss was $86.7 million versus $812.7 million in the third quarter of 2025, mainly from the change in fair value of liability-classified warrants. Vor Bio third-quarter 2026 results, 30 October 2026 · as of
- Research and development expense was $34.5 million versus $14.1 million a year earlier; general and administrative expense was $23.9 million versus $14.0 million. Vor Bio third-quarter 2026 results, 30 October 2026 · as of
- UPSTREAM MG enrollment is complete with topline anticipated in the first half of 2027; UPSTREAM SjD is enrolling. Vor Bio third-quarter 2026 results, 30 October 2026 · as of
- TELIGAN 104-week annualized eGFR slope was −0.6 on telitacicept versus −5.7 on placebo (difference 5.1, p<0.001); no kidney failure events versus five on placebo. Vor Bio release, 22 October 2026 · as of
- Vor disclosed $48.4 million of net proceeds from at-the-market share sales during July 2026. Vor Bio second-quarter 2026 results, 11 August 2026 · as of
- The shares closed at $19.32, below the 50-day average of $20.09 and above the 200-day average of $17.50, with a 16.1% three-month decline. Split/dividend-adjusted daily closes · as of
Sources
Related · shared themes
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
XNCR
Xencor
Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
See also · stocks to watch